ARU-1801 – VJRegenMed https://mirror.vjregenmed.com The Video Journal of Regenerative Medicine Tue, 16 Aug 2022 09:40:01 +0000 en-US hourly 1 https://wordpress.org/?v=6.5.2 https://d2xz56kaqxj8if.cloudfront.net/wp-content/uploads/2023/09/12102509/VJR-Favicon.png ARU-1801 – VJRegenMed https://mirror.vjregenmed.com 32 32 MOMENTUM: ARU-1801 in sickle cell disease https://mirror.vjregenmed.com/video/1dvy7xvop2i-momentum-aru-1801-in-sickle-cell-disease/ Mon, 07 Feb 2022 17:06:07 +0000 http://13.40.107.223/video/1dvy7xvop2i-momentum-aru-1801-in-sickle-cell-disease/ Will Chou, MD, Aruvant, New York, NY, presents preliminary results from the Phase I/II MOMENTUM study (NCT02186418) of ARU-1801, a lentiviral gene therapy, in patients with sickle cell disease (SCD). 5 patients are currently enrolled and the investigational therapy has a promising efficacy and safety profile, with no vaso-occlusive episodes (VOE) or hospital stays reported in patients. Dr Chou additionally reports a durable response in patients, with therapeutic hemoglobin detected in patients 3 years after initial administration. This interview took place at Advanced Therapies Week 2022.

]]>
ARU-1801, a novel lentiviral gene therapy for SCD https://mirror.vjregenmed.com/video/_9_08xotqvo-aru-1801-a-novel-lentiviral-gene-therapy-for-scd/ Thu, 03 Feb 2022 12:25:15 +0000 http://13.40.107.223/video/_9_08xotqvo-aru-1801-a-novel-lentiviral-gene-therapy-for-scd/ Current investigational therapies for sickle cell disease (SCD) require conditioning chemotherapy such as busulfan to administer the genetically-modified stem cells in the patient’s bone marrow. Will Chou, MD, Aruvant, New York, NY, provides an overview of ARU-1801, for patients with SCD. The lentiviral gene therapy uses fewer doses of an alternative chemotherapy, melphalan, which results in fewer side effects such as thrombocytopenia and veno-occlusive liver disease, as well as shorter hospital stays. This interview took place at Advanced Therapies Week 2022.

]]>